It is timely to perform a meta-analysis in order to evaluate the efficacy of azithromycin as an add-on treatment for adults with uncontrolled symptomatic asthma.
The primary outcomes that will be studied by the authors are asthma exacerbations, asthma symptoms and measures of asthma control, and lung function. I note that the authors plan to include studies in which the treatment duration is at least 4 weeks. Four weeks may be too short to show an effect on exacerbationsbest to include only studies of 6 months or 12 months duration.
One of the secondary outcomes listed is the "number or frequency of ICS inhalations for rescue use". Please clarify what you mean. Did you intend to refer to inhalations of beta2 agonists for rescue use?
It is likely that the findings of the meta-analysis will be dominated by the AMAZES study which is much larger than the rest. How will you account for this in the analysis?
There is a minor spelling error on page 3, line 32-33. "Nigh waking" should be changed to "Night waking".
Reference 10 -the author names in the citation are incorrect. Please check PubMed for correct spellings.
REVIEWER
Michael Crooks Hull York Medical School, United Kingdom REVIEW RETURNED 27-Aug-2019
GENERAL COMMENTS
This protocol paper is well written and covers an important clinical question. A recent systematic review of this topic has been published by Tian et al in J Cell Mol Med 2019. Please consider what the systematic review described in this protocol paper will add to this.
No indication is provided whether this study is already underway or the proposed timeframe for the review and subsequent publication. It would be helpful if this could be provided.
The authors indicate possible sub-group analyses with patients categorised by phenotypes. It would be helpful for further details about the proposed sub-groups and how these will be defined for the purpose of inclusion in this sub-group analysis.
The authors should review the references to ensure they are correct -e.g. the AMAZES authors are listed using their first names.
VERSION 1 -AUTHOR RESPONSE
Reviewer: 1 Comment 1 The primary outcomes that will be studied by the authors are asthma exacerbations, asthma symptoms and measures of asthma control, and lung function. I note that the authors plan to include studies in which the treatment duration is at least 4 weeks. Four weeks may be too short to show an effect on exacerbations -best to include only studies of 6 months or 12 months duration. Response: Thank you for your comment. Yes, we agree it is better to include only studies of 6 months or 12 months duration for assessing asthma exacerbations. We decided to include studies in which the treatment duration is at least 4 weeks for three reasons. First, trials which have a treatment duration of 6 months or longer is scarce. For practical considerations we did so to include as many trials as possible. Second, four weeks could be long enough to show an effect on asthma symptom control and lung function (both are primary outcomes) and most secondary outcomes. Third, we anticipate trials reporting asthma exacerbations to have longer treatment durations. Also, it is possible to make subgroup analysis to see if longer treatment could better prevent exacerbations by including trials of both short and long treatment durations. We revised the "Subgroup analysis and investigation of heterogeneity" section to include subgroup analysis based on treatment duration.
Comment 2
One of the secondary outcomes listed is the "number or frequency of ICS inhalations for rescue use". Please clarify what you mean. Did you intend to refer to inhalations of beta2 agonists for rescue use? Response:
Thanks for your comment. The GINA 2019 recommends as-needed ICS-formoterol or short-acting beta agonists (SABA) as the reliever therapy for asthma. By this outcome we intend to refer to the "number or frequency of inhalations of beta agonists with or without corticosteroids for rescue use". We have made revisions in the "Secondary outcomes" section. Reference:
The Global Initiative for Asthma Group. Pocket Guide for Asthma Management and Prevention (updated 2019). Https://ginasthma.org/wp-content/uploads/2019/04/GINA-2019-main-Pocket-Guidewms.pdf.
Comment 3
Response: Thank you for your comment. It might happen for certain outcomes. In that case we may use the fixed-effect model and make a more conservative conclusion. This is because if one trial dominates the evidence (e.g. with more than 80% of the randomized participants), the random-effect model may grossly overestimate the intervention effect. It is also sensible to conduct a sensitivity analysis and report the result from the model that yields the most conservative point estimate. If the two effect size estimates are approximately equal, the one with the widest confidence interval will be reported. We have added dicussions on this possibility in the "Data synthesis" section. Comment 4 There is a minor spelling error on page 3, line 32-33. "Nigh waking" should be changed to "Night waking". Response: Thank you for pointing this out. We have made and highlighted corrections in the manuscript.
Comment 5
Response: Thank your for pointing this out. We have checked all the author names in our reference list, and have made and highlighted corrections in the "Reference" section.
Reviewer 2: Comment 1 This protocol paper is well written and covers an important clinical question. A recent systematic review of this topic has been published by Tian et al in J Cell Mol Med 2019. Please consider what the systematic review described in this protocol paper will add to this. Response: Thanks for your information. By far, no systematic review protocol on this or similar clinical questions (azithromycin as an add-on therapy for asthma) has been published. We have carefully studied the review by Tian and others in J Cell Mol Med 2019 and compared it to our protocol. The main difference is, our proposed systematic review focuses on a more specific subgroup of the asthma patients (persistent uncontrolled asthma as defined by the GINA criteria), rather than asthma patients in general as in Tian's study. So we have stricter inclusion criteria. Specifically, we include adult patients only and propose subgroup analysis with different age groups. Also, patients must have uncontrolled persistent symptomatic asthma which warrants add-on treatment. Tian's review made no subgroup analysis of this asthma population group, and included both children and adults. Moreover, we focus on the benefit of long-term add-on use of azithromycin by including treatments lasting at least 4 weeks. Tian's study made no restriction on treatment duration, and included a trial with 3 days of azithromycin (or placebo) treatment for acute asthma exacerbations in quantitative analysis. Further limitations in Tian's 2019 systematic review which our proposed study could add to include:
1) Tian's study included two comparisons: azithromycin v.s. placebo, and azithromycin combined with other therapies v.s. other therapies alone. These therapies were not well defined, and could involve other antibiotics. We include comparisons between azithromycin and placebo or blank, on the basis of standard treatment (ICS or/and LABAs).
2) Tian and co-authors searched PubMed, EMBASE, Cochrane Controlled Trials Register databases and CNKI (a Chinese language database) from inception to 31 December 2017. Cochrane recommends all systematic reviews to be updated every second year. Compared with Tian's study, we searched three more Chinese language databases (CBM, WanFang Data and VIP) from inception to May 2019. We also searched three clinical trial registries and used Google Scholar to collect grey literature. In addition, bridging searches will be conducted to capture literature published from June 2019 until final review publication. Broader search will allow us to include more eligible trials than the previous review.
3) Tian's study did not distinguish between primary and secondary outcomes and reported five outcomes, including lung function, airway inflammation, exacerbations, symptom control and adverse events. We have clearly defined primary and secondary outcomes and include two more outcomes. 4) Only qualitative descriptions were provided for asthma exacerbations (which is our primary outcome) in Tian's study and the conclusion is inconclusive. We expect to include more studies and produce updated evidence for this important clinical question.
Comment 2
No indication is provided whether this study is already underway or the proposed timeframe for the review and subsequent publication. It would be helpful if this could be provided. Response: Thank you for your advice. This is an ongoing study. We are currently screening literature from search results. We have provided this information in the "Protocol registration and progress" section in the revised manuscript and highlighted revisions made.
Comment 3
The authors indicate possible sub-group analyses with patients categorized by phenotypes. It would be helpful for further details about the proposed sub-groups and how these will be defined for the purpose of inclusion in this sub-group analysis. Response: Thank you for your advise. We have provided more details of the proposed subgroups, and replaced the first paragraph of the "Subgroup analysis and investigation of heterogeneity" section with the following paragraph in the revised version. We will develop the following subgroup analyses to assess possible clinical heterogeneity if sufficient data are available. 1) According to different inflammatory phenotypes (e.g., eosinophilic v.s. non-eosinophilic asthma subtype based on serological test results); 2) According to different treatment durations (e.g., less than 6 months v.s. 6 months and above); 3) According to different azithromycin dosage or treatment regimens; 4) According to different patient age groups (e.g., categorizing trials into 18 to 30, 30 to 45 and above 45 age groups according to mean age); 5) Trials using blank as the comparator intervention compared to trials using placebo as the comparator intervention.
Comment 4
The authors should review the references to ensure they are correct -e.g. the AMAZES authors are listed using their first names. Thank you for pointing this out. We have made and highlighted corrections in the manuscript.
VERSION 2 -REVIEW

REVIEWER
John Upham
The University of Queensland, School of Medicine REVIEW RETURNED 24-Nov-2019
GENERAL COMMENTS
The revised manuscript is a major improvement. There are still occasional spelling and grammatical errors that need correcting. For example, "irresponsive" should be changed to an alternative word to make the meaning clearer.
REVIEWER
M Crooks
Hull York Medical School, UK REVIEW RETURNED 27-Nov-2019
VERSION 2 -AUTHOR RESPONSE
The Editor and Reviewer 1:
Comment 1
The reviewer(s) have suggested that a copyedit of your manuscript is needed. We recommend getting the language in your manuscript edited by a native English speaker or by a professional language editing service, such as Editage or American Journal Experts.
The revised manuscript is a major improvement. There are still occasional spelling and grammatical errors that need correcting.
For example, "irresponsive" should be changed to an alternative word to make the meaning clearer.
Response:
Thank you for your suggestions. We appreciate your valuable comments to help improve our manuscript.
We have had the language in our manuscript edited by a native English speaker and double-checked the revisions made using the online Grammarly copyediting service.
The word "irresponsive" in line 2 on page 3 has been replaced by "unresponsive".
